Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study)-Reference-Cited by-同舟云学术

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study)

Published:2017-07-06 Issue:11 Volume:19 Page:1513-1520
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Du Jin¹,Liang Li²,Fang Hui³,Xu Fengmei⁴,Li Wei⁵,Shen Liya⁶,Wang Xueying⁷,Xu Chun⁸,Bian Fang⁹,Mu Yiming¹^ORCID

Affiliation:

1. Department of Endocrinology; Chinese People's Liberation Army General Hospital; Beijing People's Republic of China

2. Department of Endocrinology; the People's Hospital of Liaoning Province; Shenyang People's Republic of China

3. Department of Endocrinology, Tangshan Gongren Hospital; Tangshan People's Republic of China

4. Department of Endocrinology, Hebi Coal (Group) Co., Ltd General Hospital; Hebi People's Republic of China

5. Department of Endocrinology, the Affiliated Hospital of Xuzhou Medical University; Xuzhou People's Republic of China

6. Department of Geriatrics, Wuhan 6th Hospital; Wuhan People's Republic of China

7. Department of Endocrinology, Jinzhou Central Hospital; Jinzhou People's Republic of China

8. Department of Endocrinology, Chinese People's Armed Police Force General Hospital; Beijing People's Republic of China

9. Department of Endocrinology, Cangzhou People's Hospital; Cangzhou People's Republic of China

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12942/fullpdf

Reference33 articles.

1. Diabetes in China: a societal solution for a personal challenge;Chan;Lancet Diabetes Endocrinol,2014

2. Prevalence and control of diabetes in Chinese adults;Xu;JAMA,2013

3. Causes of type 2 diabetes in China;Ma;Lancet Diabetes Endocrinol,2014

4. Urbanisation and health in China;Gong;Lancet,2012

5. Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia-Pacific region;Obes Rev,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review, meta-analysis, dose-response, and meta-regression of the effects of acarbose intake on glycemic markers in adults;Journal of Diabetes & Metabolic Disorders;2023-11-24

2. The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose–response meta-analysis of randomized clinical trials;Frontiers in Nutrition;2023-08-01

3. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey;BMJ Global Health;2023-04

4. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials;BMJ;2022-06-28

5. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study ( ACADEMIC );Diabetes, Obesity and Metabolism;2022-03-22